Head-to-head evidence
Dacomitinib PF-00299804 vs Pyrotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline
Dacomitinib PF-00299804
Marketed by Pfizer
NCT01774721 · Phase 3 · completed
The 452 participants were randomly assigned to dacomitinib or the active comparator gefitinib, but the study was open-label rather than double-blinded. The hard clinical primary endpoint, independently assessed progression-free survival, was met in favor of dacomitinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: April 2027 · NCT04946968 (registry estimate)
Pyrotinib
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04447118 · Phase 3 · completed
The study randomly assigned 151 participants to pyrotinib or active treatment with docetaxel, with the primary endpoint assessed by an independent committee blinded to treatment assignment. Because results for the progression-free survival comparison have not been posted, the trial provides limited evidence at this time despite its randomized design.
Next expected readout: December 2026 · NCT05482568 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dacomitinib PF-00299804's landscape · Pyrotinib's landscape